CD274 and metastatic neoplasm: Pembrolizumab is further approved as an initial-stage therapy for therapy-naive metastatic tumor people with PD-L1 transcription of more than 50% and metastatic tumor people with PD-L1 transcription of more than 1% after advancement following first-stage platinum-dependent doublet therapy.